** Drugmaker Amgen's AMGN.O shares fall 2.8% to $281 in extended trading
** Company says U.S. FDA placed a clinical hold on an early-stage study for its experimental weight-loss drug AMG 513
** Amgen says discussions are underway on a path forward to reopen the study
** Company posts Q4 adj profit of $5.31/shr vs analysts' average est. of $5.08/shr - LSEG
** Up to last close, stock down 10.2% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。